Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.
Is this guidance up to date?
This guidance has been updated to include a review of the cost model using more recent values. New evidence and updated costs identified during the guidance review are denoted as .
Next review: March 2022
Guidance development process
NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
Coding relevant to this guidance
NICE guidance states that this is for use in a community setting, this being primary care. OPCS-4 is only mandated for use in secondary care in the admitted patient care dataset. As this would be carried out by a nurse in community setting no OPCS-4 code would be assigned. Unless this is being considered for inpatients, the patients would need to be admitted under a consultant in order that and FCE to be generated OPCS-4 code assigned.
Possible OPCS-4 code if needed: wound debridement S57.1
939871000000108 | Debridement of wound of skin using debridement pad (procedure)
19273111000001103 | Physical debridement pad (physical object)
19257811000001102 | DebriSoft pad 10cm x 10cm (Activa Healthcare Ltd) (physical object)
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.